Tech Company Financing Transactions
Zalicus Funding Round
Zalicus, based in Cambridge, scored $30 million from Boston Millennia Partners, Canaan Partners and Easton Capital.
Transaction Overview
Company Name
Announced On
3/10/2004
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series C
Investors
Boston Millennia Partners (Lead Investor) (Patrick Fortune)
Proceeds Purpose
The funds from this financing will be used to progress multiple programs from the CombinatoRx pipeline through the clinic.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
245 First St. 3rd Floor
Cambridge, MA 02142
USA
Cambridge, MA 02142
USA
Phone
Website
Email Address
Overview
Our pipeline includes Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time and Synavive, in Phase 2 development for rheumatoid arthritis.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Mark Corrigan
Chief Financial Officer
Justin Renz
Browse more venture capital transactions:
Prev: 3/10/2004: Phylogix venture capital transaction
Next: 3/11/2004: BioRexis Pharmaceutical venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on tech company VC transactions. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs